HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Grabs Europe Rights to 1st-in-Class Cholesterol Drug
January 8, 2019
- Fujifilm to Make 10 Billion Yen Capital Investment in Bio CDMO Business
January 8, 2019
- Kaken Licenses Systemic Sclerosis Treatment from Corbus in Japan
January 8, 2019
- J-TEC’s Cell Sheet JACE Approved for Epidermolysis Bullosa
January 8, 2019
- Sumitomo Dainippon Corrects Announcement on US Latuda Settlement
January 7, 2019
- JCR Completes Patient Enrolment in Japan PIII Study for Hunter Syndrome Treatment
January 7, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
- Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?
January 4, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
- Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan
December 28, 2018
- Kyorin, Hebrew University Link Arms in Respiratory Drug Development
December 28, 2018
- Ono Files Heart Failure Drug Ivabradine in Japan
December 28, 2018
- Chugai Obtains Approval of First Dual-Function Gene Panel Test
December 28, 2018
- Biogen Japan Set to “Make Impossible Possible” in Next 5 Years, Double Neuroscience Pipeline
December 27, 2018
- Crestor Generics of Nichi-Iko, Towa Now Have Full Indications
December 27, 2018
- Xofluza Most Heavily Promoted Drug for GP in October: Anterio
December 27, 2018
- First Cancer Gene Panel Test Approved in Japan: Sysmex
December 27, 2018
- Japan Vaccine to Transfer Business to Daiichi Sankyo, GSK in April
December 27, 2018
- Fuji Pharma Shooting for 2.6-Fold Sales Increase by 2030: President
December 26, 2018
- Sumitomo Dainippon to Merge Authorized Generic Units
December 26, 2018
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
